Feasibility of known rna polymerase inhibitors as anti-sars-cov-2 drugs

Ujjwal Neogi, Kyle J. Hill, Anoop T. Ambikan, Xiao Heng, Thomas P. Quinn, Siddappa N. Byrareddy, Anders Sönnerborg, Stefan G. Sarafianos, Kamal Singh

Research output: Contribution to journalArticle

Abstract

Coronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E,-NL63,-OC43 and-HKU1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases with mortality rates ranging between ~1 to 35% depending on factors such as age and pre-existing conditions. Despite continuous global health threats to humans, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti-SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.

Original languageEnglish (US)
Article number320
JournalPathogens
Volume9
Issue number5
DOIs
StatePublished - May 2020

Keywords

  • COVID-19
  • Coronavirus
  • MERS-CoV
  • Nsp12
  • RNA polymerase
  • SARS-CoV
  • SARS-CoV-2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Molecular Biology
  • Immunology and Microbiology(all)
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Feasibility of known rna polymerase inhibitors as anti-sars-cov-2 drugs'. Together they form a unique fingerprint.

  • Cite this

    Neogi, U., Hill, K. J., Ambikan, A. T., Heng, X., Quinn, T. P., Byrareddy, S. N., Sönnerborg, A., Sarafianos, S. G., & Singh, K. (2020). Feasibility of known rna polymerase inhibitors as anti-sars-cov-2 drugs. Pathogens, 9(5), [320]. https://doi.org/10.3390/pathogens9050320